CytomX Therapeutics Inc Gets a Hold Rating from Oppenheimer


Oppenheimer analyst Leah R. Cann assigned a Hold rating to CytomX Therapeutics Inc (NASDAQ: CTMX) today. The company’s shares opened today at $24.61.

Cann noted:

“CytomX announced in June 2017 its plans to file an IND for CX-2029 in 2018; therefore, the timing of this filing is in line with expectations. CX-2029 is now CytomX’s third drug in development, along with CX-072 and CX-2009. Filing an IND for third compound is very supportive of the strength of the platform. Our estimates remain unchanged, based on the early stage of development of this program.”

According to TipRanks.com, Cann is a 5-star analyst with an average return of 17.7% and a 61.2% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, Crispr Therapeutics AG, and Intellia Therapeutics.

CytomX Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $40.

See today’s analyst top recommended stocks >>

The company has a one-year high of $35 and a one-year low of $13. Currently, CytomX Therapeutics Inc has an average volume of 380.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CytomX Therapeutics, Inc. operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer. The company was founded in September, 2010 and is headquartered in South San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts